Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
1999-08-06
2003-09-30
Low, Christopher S. F. (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C514S006900, C436S015000, C436S066000
Reexamination Certificate
active
06627738
ABSTRACT:
BACKGROUND OF THE INVENTION
Interactions of hemoglobin (Hb) with small diffusible ligands, such as O
2
, CO
2
and NO, are known to occur at its metal centers and amino termini. The O
2
/CO
2
delivery functions, which arise in the lung and systemic microvasculature, are allosterically controlled. Such responsiveness to the environment has not been known to apply in the case of NO. Specifically, it has been thought previously that NO does not modify the functional properties of Hb to any physiologically significant degree. Kinetic modeling predicts that the vast majority of free NO in the vasculature should be scavenged by Hb (Lancaster 1994). Accordingly, the steady-state level of NO may fall below the K
m
for target enzymes such as guanylate cyclase (Lancaster 1994), if not in the unperturbed organism, then with oxidant stress such as that found in atherosclerosis. These considerations raise the fundamental question of how NO exerts its biological activity.
One answer to this question is found in the propensity of nitric oxide to form S-nitrosothiols (RSNOS) (Gaston, B. et al.,
Proc. Natl. Acad. Sci. USA
90:10957-10961 (1993)), which retain NO-like vasorelaxant activity (Stamler, J. S., et al.,
Proc. Natl. Acad. Sci. USA
89:444-448 (1992)), but which can pass freely in and out of cells, unlike Hb. In particular, the NO group of RSNOs possesses nitrosonium (NO
+
) character that distinguishes it from NO itself. It is increasingly appreciated that RSNOs have the capacity to elicit certain functions that NO is incapable of (DeGroote, M. A. et al.,
Proc. Natl. Acad. Sci. USA
92:6399-6403 (1995); Stamler, J. S.,
Cell
78:931-936 (1994)). Moreover, consideration has been given to the possibility that —SNO groups in proteins serve a signaling function, perhaps analogous to phosphorylation (Stamler, J. S. et al.,
Proc. Natl. Acad. Sci. USA
89:444-448 (1992); Stamler, J. S.
Cell,
78:931-926 (1994)). Although S-nitrosylation of proteins can regulate protein function (Stamler, J. S. et al.,
Proc. Natl. Acad. Sci. USA
89:444-448 (1992); Stamler, J. S.,
Cell,
78:931-936 (1994)), intracellular S-nitrosoproteins—the sine qua non of a regulatory posttranslational modification—has heretofore not been demonstrated.
Hemoglobin is a tetramer composed of two alpha and two beta subunits. In human Hb, each subunit contains one heme, while the beta (&bgr;) subunits also contain highly reactive SH groups (cys&bgr;93) (Olson, J. S.,
Methods in Enzymology
76:631-651 (1981); Antonini, E. & Brunori, M. In
Hemoglobin and Myoglobin in Their Reactions with Ligands,
American Elsevier Publishing Co., Inc., New York, pp. 29-31 (1971)). These cysteine residues are highly conserved among species although their function has remained elusive.
NO (nitric oxide) is a biological “messenger molecule” which decreases blood pressure and inhibits platelet function, among other functions. NO freely diffuses from endothelium to vascular smooth muscle and platelet and across neuronal synapses to evoke biological responses. Under some conditions, reactions of NO with other components present in cells and in serum can generate toxic intermediates and products at local concentrations in tissues which are effective at inhibiting the growth of infectious organisms. Thus, it can be seen that a method of administering an effective concentration of NO or biologically active forms thereof would be beneficial in certain medical disorders.
Platelet activation is an essential component of blood coagulation and thrombotic diathesis. Activation of platelets is also seen in hematologic disorders such as sickle cell disease, in which local thrombosis is thought to be central to the painful crisis. Inhibition of platelet aggregation is therefore an important therapeutic goal in heart attacks, stroke, and shock (disseminated intravascular coagulation) and in chronic conditions such as peripheral vascular disease, heart disease, brain disease, lung disease and atherosclerosis. Researchers have attempted to give artificial hemoglobins to enhance oxygen delivery in all of the above disease states. However, as recently pointed out by Olsen and coworkers, administration of underivatized hemoglobin leads to platelet activation at sites of vascular injury (Olsen S. B. et al.,
Circulation
93:327-332 (1996)). This major problem has led experts to conclude that cell-free underivatized hemoglobins pose a significant risk of causing blood clots in the patient with vascular disease or a clotting disorder (Marcus, A. J. and J. B. Broekman,
Circulation
93:208-209 (1996)). New methods of providing for an oxygen carrier and/or a method of inhibiting platelet activation would be of benefit to patients with vascular disease or who are otherwise at risk for thrombosis.
SUMMARY OF THE INVENTION
The invention relates to methods of producing and isolating SNO-Hb (S-nitrosohemoglobin, which includes for instance, oxy-, deoxy-, or met- hemoglobin for use in therapy) by reaction of Hb with S-nitrosothiol in procedures which avoid oxidation of the heme. The invention also includes methods of producing isolated, nitrosated (including nitrosylated at thiols or metals) and nitrated derivatives of hemoglobins in which the heme Fe can be oxidized or not oxidized, depending on the steps of the method. The invention also relates to a method of therapy for a condition in which it is desired to oxygenate, to scavenge free radicals, or to release NO
+
groups or other forms of biologically active NO to tissues. A composition comprising SNO-Hb in its various forms and combinations thereof (oxy, deoxy, met; specifically S-nitrosylated, or nitrosated or nitrated to various extents) can be administered to an animal or human in these methods. Compositions comprising thiols and/or NO donating agents can also be administered to enhance the transfer of NO
+
groups. Examples of conditions to be treated by nitrosated or nitrated forms of hemoglobin include ischemic injury, hypertension, angina, reperfusion injury and inflammation, and diseases characterized by thrombosis. Further embodiments of the invention are methods for assessing oxygen delivery to the tissues of a mammal by measuring SNO-Hb and nitrosylhemoglobin in blood.
REFERENCES:
patent: 3973910 (1976-08-01), Fine
patent: 3996008 (1976-12-01), Fine et al.
patent: 4066411 (1978-01-01), Fine et al.
patent: 4193963 (1980-03-01), Bruening et al.
patent: 4236895 (1980-12-01), Stahl
patent: 4657744 (1987-04-01), Howard
patent: 4822564 (1989-04-01), Howard
patent: 4900719 (1990-02-01), Means et al.
patent: 5094815 (1992-03-01), Conboy et al.
patent: 5116861 (1992-05-01), Goto et al.
patent: 5152979 (1992-10-01), Hunter
patent: 5346599 (1994-09-01), Stamler et al.
patent: 5366900 (1994-11-01), Conboy et al.
patent: 5380758 (1995-01-01), Stamler et al.
patent: 5380824 (1995-01-01), Marschall et al.
patent: 5385937 (1995-01-01), Stamler et al.
patent: 5395314 (1995-03-01), Klatz et al.
patent: 5405919 (1995-04-01), Keefer et al.
patent: 5427797 (1995-06-01), Frostell et al.
patent: 5439882 (1995-08-01), Feola et al.
patent: 5459076 (1995-10-01), Stamler et al.
patent: 5464814 (1995-11-01), Sehgal et al.
patent: 5480866 (1996-01-01), Bonaventura et al.
patent: 5525357 (1996-06-01), Keefer et al.
patent: 5543430 (1996-08-01), Kaesemeyer
patent: 5574068 (1996-11-01), Stamler et al.
patent: 5583101 (1996-12-01), Stamler et al.
patent: 5591710 (1997-01-01), Hsia
patent: 5593876 (1997-01-01), Stamler et al.
patent: 6087479 (2000-07-01), Stamler et al.
patent: 6291424 (2001-09-01), Stamler et al.
patent: WO 93/09806 (1993-05-01), None
patent: WO 93/21525 (1993-10-01), None
patent: WO 94/22306 (1994-10-01), None
patent: WO 94/22482 (1994-10-01), None
patent: WO 94/22499 (1994-10-01), None
patent: WO 95/05397 (1995-02-01), None
patent: WO 95/07691 (1995-03-01), None
patent: WO 96/03139 (1996-02-01), None
patent: WO 96/15797 (1996-05-01), None
patent: WO 96/16645 (1996-06-01), None
patent: WO 96/17604 (1996-06-01), None
patent: WO 96/30006 (1996-10-01), None
patent: WO 97/18000 (1997-05-01), None
patent:
Gow Andrew J.
Stamler Jonathan S.
Duke University
Low Christopher S. F.
Lukton David
LandOfFree
No-modified hemoglobins and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with No-modified hemoglobins and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and No-modified hemoglobins and uses therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3030249